Development and validation of long-acting recombinant human TSH using SAFA technology
Endocrine-Related Cancer · 2025
DOI: 10.1530/erc-24-0284 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Endocrine-Related Cancer, 2025. Verfasst von Daham Kim und 10 weiteren Autor:innen. Hauptthemen laut MEDLINE: Thyrotropin, Serum Albumin. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIEHS NIH HHS, Korea Health Industry Development Institute, Ministry of Health and Welfare.
Abstract (Originalsprache)
Thyrogen, a recombinant human thyroid-stimulating hormone (rhTSH), has a short half-life in the bloodstream, which necessitates multiple doses during treatment. Therefore, we developed a new long-acting rhTSH using anti-serum albumin Fab-associated (SAFA) technology to validate its biological activity through in vitro assays, pharmacokinetic studies in healthy mice and pharmacodynamics studies in a thyroid-stimulating hormone (TSH)-suppressed mouse model. SAFA-TSH was produced using a Chinese hamster ovary expression system. To verify its biological activity, we generated Nthy-ori 3-1 cells stably overexpressing TSHR and measured the production of cyclic adenosine monophosphate (cAMP). In a rat study, slow-release triiodothyronine (T3) pellets were implanted 3 days before administering Thyrogen or SAFA-TSH to measure the amount of thyroxine (T4) release alone resulting from exogenous administration. SAFA-TSH increased cAMP production dose-dependently, but less effectively than Thyrogen at similar concentrations. SAFA-TSH required six times the dose of Thyrogen to achieve similar cAMP levels, likely due to differences in molecular weight and relative bioactivity. In a rat study, SAFA-TSH produced elevated thyroid hormone levels well after the decline in the response to Thyrogen. SAFA-TSH had significantly higher cumulative effects on T4 and free T4 levels compared with Thyrogen, as observed by a more than two-fold higher average area under the effect curve of 262.56 vs 118.89 μg × h/dL and 127.47 vs 60.75 μg × h/dL, respectively. SAFA technology created successful long-acting TSH that demonstrated bioactivity. These findings endorse the continued development of SAFA-TSH for clinical use, highlighting its potential as a significant advancement treating thyroid cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
ORCID-Profile: Daham Kim, Yoon Hee Cho, Eun Jig Lee
Förderung
- NIEHS NIH HHS
- Korea Health Industry Development Institute
- Ministry of Health and Welfare
Zitieren
APA
Kim, D., Kang, M. J., Lee, S. J., Cho, Y. H., Zi, G., An, J., Park, J., Han, J., Chi, S., Cha, S. H., & Lee, E. J. (2025). Development and validation of long-acting recombinant human TSH using SAFA technology. Endocrine-Related Cancer. https://doi.org/10.1530/erc-24-0284
Vancouver
Kim D, Kang MJ, Lee SJ, Cho YH, Zi G, An J, et al. Development and validation of long-acting recombinant human TSH using SAFA technology. Endocrine-Related Cancer. 2025. doi:10.1530/erc-24-0284
BibTeX
@article{Kim2025,
author = {Kim, Daham and Kang, Min Jeong and Lee, So Jeong and Cho, Yoon Hee and Zi, Gunuk and An, Jeongsuk and Park, Jinjoo and Han, Jaekyu and Chi, Susan and Cha, Sang-Hoon and Lee, Eun Jig},
title = {Development and validation of long-acting recombinant human TSH using SAFA technology},
journal = {Endocrine-Related Cancer},
year = {2025},
doi = {10.1530/erc-24-0284}
}
EUVIMED